Medical Editor: John P. Cunha, DO, FACOEP
What Is Netspot?
Netspot (kit for the preparation of gallium Ga 68 dotatate injection), after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
What Are Side Effects of Netspot?
Side effects of Netspot are not expected. Tell your doctor if you experience any side effects while Netspot is administered.
Dosage for Netspot
Netspot is supplied as a single dose kit containing: Vial 1 (reaction vial with lyophilized powder) containing 40 mcg of dotatate, and Vial 2 (buffer vial) containing 1 mL of reaction buffer solution.
What Drugs, Substances, or Supplements Interact with Netspot?
Netspot may interact with non-radioactive somatostatin analogs. Tell your doctor all medications and supplements you use.
Netspot During Pregnancy or Breastfeeding
Netspot is not recommended for use during pregnancy. All radiopharmaceuticals, Netspot, have the potential to cause fetal harm. Netspot is not recommended for use while breastfeeding. Breast milk should be pumped and discarded for 12 hours after administration of Netspot.
Our Netspot (kit for the preparation of gallium Ga 68 dotatate injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
The safety of Ga 68 dotatate was evaluated in three single center studies [see Clinical Studies] and in a survey of the scientific literature. No serious adverse reactions were identified.
The following adverse reactions have been identified during post-approval use of NETSPOT or other somatostatin receptor imaging agents. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug.
Gastrointestinal Disorders: Nausea and vomiting
General Disorders and Administration Site Conditions: Injection site pain and burning sensation
Immune System Disorders: Hypersensitivity reactions, predominantly rash, pruritus, less frequently angioedema or features of anaphylaxis.
Non-radioactive somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate. Image patients with Ga 68 dotatate PET just prior to dosing with long-acting analogs of somatostatin. Shortacting analogs of somatostatin can be used up to 24 hours before imaging with Ga 68 dotatate.
Corticosteroids can down-regulate somatostatin subtype 2 receptors. Repeated administration of high doses of glucocorticoid prior to Ga 68 dotatate administration may result in false negative imaging.
Read the entire FDA prescribing information for Netspot (Gallium Ga 68 Dotatate Kit)
© Netspot Patient Information is supplied by Cerner Multum, Inc. and Netspot Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.